Peter Barrett‐Lee

9.9k total citations · 2 hit papers
121 papers, 5.0k citations indexed

About

Peter Barrett‐Lee is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Peter Barrett‐Lee has authored 121 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 37 papers in Cancer Research and 34 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Peter Barrett‐Lee's work include Breast Cancer Treatment Studies (35 papers), HER2/EGFR in Cancer Research (28 papers) and Cancer Treatment and Pharmacology (27 papers). Peter Barrett‐Lee is often cited by papers focused on Breast Cancer Treatment Studies (35 papers), HER2/EGFR in Cancer Research (28 papers) and Cancer Treatment and Pharmacology (27 papers). Peter Barrett‐Lee collaborates with scholars based in United Kingdom, United States and Belgium. Peter Barrett‐Lee's co-authors include Judith M. Bliss, R. Charles Coombes, Pere Gascón, Carsten Bokemeyer, M. Schneider, Dirk Schrijvers, M T Travers, Stephen Hiscox, Penelope Hopwood and Simon Van Belle and has published in prestigious journals such as The Lancet, Nature Genetics and Journal of Clinical Oncology.

In The Last Decade

Peter Barrett‐Lee

118 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials

2013 940 citations Peter Barrett‐Lee, Judith M. Bliss et al. The Lancet Oncology profile →
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients

2004 678 citations Peter Barrett‐Lee et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Barrett‐Lee United Kingdom	35	2.6k	1.4k	885	828	807	121	5.0k
David Dodwell United Kingdom	39	2.9k 1.1×	1.9k 1.4×	624 0.7×	1.1k 1.3×	474 0.6×	188	5.5k
L. Campion France	42	1.9k 0.7×	1.4k 1.0×	2.2k 2.5×	1.1k 1.4×	1.0k 1.3×	185	6.2k
Michael L. Cher United States	42	2.0k 0.8×	1.6k 1.2×	1.9k 2.1×	437 0.5×	222 0.3×	165	5.5k
Constance Cirrincione United States	38	6.8k 2.7×	4.7k 3.4×	1.3k 1.5×	1.1k 1.3×	639 0.8×	81	9.8k
Christopher Poole United Kingdom	26	1.7k 0.7×	994 0.7×	734 0.8×	220 0.3×	154 0.2×	65	3.7k
Steinbjørn Hansen Denmark	34	1.7k 0.7×	1.6k 1.2×	1.5k 1.7×	1.3k 1.6×	583 0.7×	92	5.7k
Orazio Caffo Italy	36	2.4k 0.9×	1.4k 1.0×	1.4k 1.5×	662 0.8×	202 0.3×	230	4.8k
Silvana Martino Italy	31	1.6k 0.6×	1.2k 0.8×	781 0.9×	443 0.5×	353 0.4×	72	4.6k
Enrico Cortesi Italy	41	4.7k 1.8×	1.5k 1.1×	1.2k 1.3×	410 0.5×	170 0.2×	266	7.2k
Mary Ellen Taplin United States	16	1.6k 0.6×	1.0k 0.8×	924 1.0×	962 1.2×	432 0.5×	27	5.1k

Countries citing papers authored by Peter Barrett‐Lee

Since Specialization

Citations

This map shows the geographic impact of Peter Barrett‐Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Barrett‐Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Barrett‐Lee more than expected).

Fields of papers citing papers by Peter Barrett‐Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Barrett‐Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Barrett‐Lee. The network helps show where Peter Barrett‐Lee may publish in the future.

Co-authorship network of co-authors of Peter Barrett‐Lee

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Barrett‐Lee. A scholar is included among the top collaborators of Peter Barrett‐Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Barrett‐Lee. Peter Barrett‐Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Symeonides, Stefan N., Duncan Wheatley, Stephen Chan, et al.. (2023). Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study. Breast Cancer Research and Treatment. 199(1). 35–46. 8 indexed citations

Harper, Paul, et al.. (2021). Modified Needleman–Wunsch algorithm for clinical pathway clustering. Journal of Biomedical Informatics. 115. 103668–103668. 8 indexed citations

Muller, Ilaria & Peter Barrett‐Lee. (2019). The antigenic link between thyroid autoimmunity and breast cancer. Seminars in Cancer Biology. 64. 122–134. 18 indexed citations

Silva, Andreia, Tim Robinson, Angélica Santiago-Gómez, et al.. (2018). Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP. Clinical Cancer Research. 24(10). 2452–2463. 42 indexed citations

Muller, Ilaria, Lucy Kilburn, Peter Taylor, et al.. (2017). TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). European Thyroid Journal. 6(4). 197–207. 17 indexed citations

Smith, Christopher R., Julia M.W. Gee, Ursula Günthert, et al.. (2016). Overexpression of Specific CD44 Isoforms Is Associated with Aggressive Cell Features in Acquired Endocrine Resistance. Frontiers in Oncology. 6. 145–145. 20 indexed citations

Burcombe, Russell, et al.. (2015). Subcutaneous trastuzumab (Herceptin®): A UK time and motion study in comparison with intravenous formulation for the treatment of patients with HER2-positive early breast cancer. Oncology in Clinical Practice. 11(1). 30–39. 1 indexed citations

Irshad, Sheeba, Cheryl Gillett, S Pinder, et al.. (2014). Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment. 144(2). 331–341. 4 indexed citations

Coleman, Robert E., David Cameron, David Dodwell, et al.. (2014). Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology. 15(9). 997–1006. 202 indexed citations

10.

Smith, Christopher R., Lindy Goddard, Nicola Jordan, et al.. (2013). Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response. Endocrine Related Cancer. 20(5). 691–704. 31 indexed citations

11.

Barrett‐Lee, Peter, Angela Casbard, Jacinta Abraham, et al.. (2013). Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial. The Lancet Oncology. 15(1). 114–122. 83 indexed citations

12.

Jasani, Bharat, et al.. (2011). Exploring the use and impact of adjuvant Trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. British Journal of Cancer. 106(1). 32–38. 19 indexed citations

13.

Binda, Elisa, et al.. (2010). Human gammadelta T cell responses in breast cancer patients during zoledronate therapy. ORCA Online Research @Cardiff (Cardiff University).

14.

Cavill, Ivor, Michael Auerbach, George R. Bailie, et al.. (2006). Iron and the anaemia of chronic disease: a review and strategic recommendations. Current Medical Research and Opinion. 22(4). 731–737. 61 indexed citations

15.

Barrett‐Lee, Peter. (2005). Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: a review of chemotherapy. Endocrine Related Cancer. 12(Supplement_1). S125–S133. 22 indexed citations

16.

Wardley, Andrew, N. Davidson, Peter Barrett‐Lee, et al.. (2005). Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration. British Journal of Cancer. 92(10). 1869–1876. 121 indexed citations

17.

Barrett‐Lee, Peter, N P Bailey, Mary O’Brien, & Elizabeth Wager. (2000). Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy. British Journal of Cancer. 82(1). 93–97. 127 indexed citations

18.

Bottrill, Ian, Simon Wood, Peter Barrett‐Lee, & David Howard. (1994). Mesenchymal chondrosarcoma of the maxilla. The Journal of Laryngology & Otology. 108(9). 785–787. 11 indexed citations

19.

Murray, P, Peter Barrett‐Lee, M T Travers, et al.. (1993). The prognostic significance of transforming growth factors in human breast cancer. British Journal of Cancer. 67(6). 1408–1412. 68 indexed citations

20.

Wooster, Richard, Jonathan Mangion, Rosalind A. Eeles, et al.. (1992). A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nature Genetics. 2(2). 132–134. 165 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact